Premium
DOTS and DOTS‐Plus
Author(s) -
FARMER PAUL
Publication year - 2001
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2001.tb11375.x
Subject(s) - tuberculosis , transmission (telecommunications) , short course , multiple drug resistance , medicine , pandemic , epidemiology , intensive care medicine , immunology , covid-19 , computer science , drug resistance , disease , pediatrics , telecommunications , biology , pathology , infectious disease (medical specialty) , microbiology and biotechnology
A bstract : Multidrug‐resistant tuberculosis is already a global pandemic, with focal “hot spots” of ongoing transmission. Although DOTS (directly observed treatment, short course) chemotherapy is the goal of global tuberculosis control, short‐course chemotherapy will not cure multidrug‐resistant tuberculosis. In settings of high transmission of multidrug‐resistant tuberculosis, “DOTS plus” (a complementary DOTS‐based strategy with provisions for treating multidrug‐resistant tuberculosis) is warranted. DOTS‐plus project implementation to date reveals important clinical, epidemiological, and economic lessons. Community‐based strategies designed to enhance local capacity are cost effective and make it possible to meet new medical challenges.